Subscribe to RSS
DOI: 10.1055/s-0041-1730946
The Deteriorating Patient: Therapies Including Lung Transplantation
Funding None.![](https://www.thieme-connect.de/media/srccm/202104/lookinside/thumbnails/10-1055-s-0041-1730946_210414-1.jpg)
Abstract
In this review paper, we discuss the characteristics that define severe bronchiectasis and which may lead to deterioration of noncystic fibrosis bronchiectasis. These characteristics were used to establish the current severity scores: bronchiectasis severity index (BSI), FACED, and E-FACED (exacerbation frequency, forced expiratory volume in 1 second, age, colonization, extension and dyspnea score). They can be used to predict mortality, exacerbation rate, hospital admission, and quality of life. Furthermore, there are different treatable traits that contribute to severe bronchiectasis and clinical deterioration. When present, they can be a target of the treatment to stabilize bronchiectasis.
One of the first steps in treatment management of bronchiectasis is evaluation of compliance to already prescribed therapy. Several factors can contribute to treatment adherence, but to date no real interventions have been published to ameliorate this phenomenon. In the second step, treatment in deteriorating patients with bronchiectasis should be guided by the predominant symptoms, for example, cough, sputum, difficulty expectoration, exacerbation rate, or physical impairment. In the third step, we evaluate treatable traits that could influence disease severity in the deteriorating patient. Finally, in patients who are difficult to treat despite maximum medical treatment, eligibility for surgery (when disease is localized), should be considered. In case of end-stage disease, the evaluation for lung transplantation should be performed. Noninvasive ventilation can serve as a bridge to lung transplantation in patients with respiratory failure.
Publication History
Article published online:
14 July 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis 2017; 14 (04) 377-384
- 2 Quint JK, Millett ERC, Joshi M. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47 (01) 186-193
- 3 Diel R, Ewig S, Blaas S. et al. Incidence of patients with non-cystic fibrosis bronchiectasis in Germany: a healthcare insurance claims data analysis. Respir Med 2019; 151: 121-127
- 4 Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010; 104 (07) 981-985
- 5 Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One 2013; 8 (08) e71109
- 6 Goeminne PC, Hernandez F, Diel R. et al. The economic burden of bronchiectasis - known and unknown: a systematic review. BMC Pulm Med 2019; 19 (01) 54
- 7 Bahous J, Cartier A, Pineau L. et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984; 20 (04) 375-380
- 8 Chalmers JD, Goeminne P, Aliberti S. et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189 (05) 576-585
- 9 Roberts HR, Wells AU, Milne DG. et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000; 55 (03) 198-204
- 10 Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132 (05) 1565-1572
- 11 Serisier DJ, Martin ML, McGuckin MA. et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309 (12) 1260-1267
- 12 Chalmers JD, Boersma W, Lonergan M. et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med 2019; 7 (10) 845-854
- 13 Bellelli G, Chalmers JD, Sotgiu G. et al. Characterization of bronchiectasis in the elderly. Respir Med 2016; 119: 13-19
- 14 Martínez-García MA, de Gracia J, Vendrell Relat M. et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43 (05) 1357-1367
- 15 Loebinger MR, Wells AU, Hansell DM. et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34 (04) 843-849
- 16 Chalmers JD, Aliberti S, Filonenko A. et al. Characterisation of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med 2018; 197 (11) 1410-1420
- 17 Bradley JM, Wilson JJ, Hayes K. et al. Sedentary behaviour and physical activity in bronchiectasis: a cross-sectional study. BMC Pulm Med 2015; 15: 61
- 18 de Camargo AA, Boldorini JC, Holland AE. et al. Determinants of peripheral muscle strength and activity in daily life in people with bronchiectasis. Phys Ther 2018; 98 (03) 153-161
- 19 Ozalp O, Inal-Ince D, Calik E. et al. Extrapulmonary features of bronchiectasis: muscle function, exercise capacity, fatigue, and health status. Multidiscip Respir Med 2012; 7 (01) 3
- 20 Qi Q, Li T, Li JC, Li Y. Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis. Braz J Med Biol Res 2015; 48 (08) 715-724
- 21 Vestbo J, Hurd SS, Agustí AG. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187 (04) 347-365
- 22 Konstantinides SV, Meyer G, Becattini C. et al. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54 (03) 1901647
- 23 Lim WS, van der Eerden MM, Laing R. et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58 (05) 377-382
- 24 Martinez-Garcia MA, Athanazio RA, Girón R. et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis 2017; 12: 275-284
- 25 McDonnell MJ, Aliberti S, Goeminne PC. et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med 2016; 4 (12) 969-979
- 26 Rosales-Mayor E, Polverino E, Raguer L. et al. Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. PLoS One 2017; 12 (04) e0175171
- 27 Ellis HC, Cowman S, Fernandes M, Wilson R, Loebinger MR. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J 2016; 47 (02) 482-489
- 28 McDonnell MJ, Aliberti S, Goeminne PC. et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax 2016; 71 (12) 1110-1118
- 29 Minov J, Karadzinska-Bislimovska J, Vasilevska K, Stoleski S, Mijakoski D. Assessment of the non-cystic fibrosis bronchiectasis severity: the FACED score vs the bronchiectasis severity index. Open Respir Med J 2015; 9: 46-51
- 30 Goeminne PC, Kiciński M, Vermeulen F. et al. Impact of air pollution on cystic fibrosis pulmonary exacerbations: a case-crossover analysis. Chest 2013; 143 (04) 946-954
- 31 Farhat SCL, Almeida MB, Silva-Filho LVRF, Farhat J, Rodrigues JC, Braga ALF. Ozone is associated with an increased risk of respiratory exacerbations in patients with cystic fibrosis. Chest 2013; 144 (04) 1186-1192
- 32 Jassal MS, Yu AM, Bhatia R, Keens TG, Davidson Ward SL. Effect of residential proximity to major roadways on cystic fibrosis exacerbations. Int J Environ Health Res 2013; 23 (02) 119-131
- 33 Goss CH, Newsom SA, Schildcrout JS, Sheppard L, Kaufman JD. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med 2004; 169 (07) 816-821
- 34 Goeminne PC, Bijnens E, Nemery B, Nawrot TS, Dupont LJ. Impact of traffic related air pollution indicators on non-cystic fibrosis bronchiectasis mortality: a cohort analysis. Respir Res 2014; 15 (01) 108
- 35 Garcia-Olivé I, Stojanovic Z, Radua J, Rodriguez-Pons L, Martinez-Rivera C, Ruiz Manzano J. Effect of air pollution on exacerbations of bronchiectasis in Badalona, Spain, 2008-2016. Respiration 2018; 96 (02) 111-116
- 36 Raji H, Riahi A, Borsi SH. et al. Acute effects of air pollution on hospital admissions for asthma, COPD, and bronchiectasis in Ahvaz, Iran. Int J Chron Obstruct Pulmon Dis 2020; 15: 501-514
- 37 Goeminne PC, Cox B, Finch S. et al. The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. Eur Respir J 2018; 52 (01) 1-11
- 38 Wang Z, Zhou Y, Zhang Y. et al. Association of hospital admission for bronchiectasis with air pollution: a province-wide time-series study in southern China. Int J Hyg Environ Health 2021; 231: 113654
- 39 Kumar R, Chopra D. Evaluation of allergic bronchopulmonary aspergillosis in patients with and without central bronchiectasis. J Asthma 2002; 39 (06) 473-477
- 40 Wark PA, Saltos N, Simpson J, Slater S, Hensley MJ, Gibson PG. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. Eur Respir J 2000; 16 (06) 1095-1101
- 41 Greenberger PA, Miller TP, Roberts M, Smith LL. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy 1993; 70 (04) 333-338
- 42 Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: 1-58
- 43 Stevens DA, Schwartz HJ, Lee JY. et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342 (11) 756-762
- 44 Polverino E, Dimakou K, Hurst J. et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J 2018; 52 (03) 1-18
- 45 Luján M, Gallardo X, Amengual MJ, Bosque M, Mirapeix RM, Domingo C. Prevalence of bronchiectasis in asthma according to oral steroid requirement: influence of immunoglobulin levels. BioMed Res Int 2013; 2013: 109219
- 46 Dupin C, Marchand-Adam S, Favelle O. et al. Asthma and hypogammaglobulinemia: an asthma phenotype with low type 2 inflammation. J Clin Immunol 2016; 36 (08) 810-817
- 47 Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014; 108 (02) 287-296
- 48 Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One 2016; 11 (03) e0150532
- 49 Hill AT, Sullivan AL, Chalmers JD. et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74 (Suppl. 01) 1-69
- 50 Crisafulli E, Guerrero M, Ielpo A. et al. Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. Sci Rep 2018; 8 (01) 9236
- 51 Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease. Respir Med 2013; 107 (09) 1385-1392
- 52 Altenburg J, de Graaff CS, Stienstra Y. et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309 (12) 1251-1259
- 53 Wong C, Jayaram L, Karalus N. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380 (9842): 660-667
- 54 Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012; 13 (01) 21
- 55 Mandal P, Morice AH, Chalmers JD, Hill AT. Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 2013; 107 (07) 1008-1013
- 56 McDonnell MJ, Ahmed M, Das J. et al. Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis. Respirology 2015; 20 (05) 749-757
- 57 Ahn B, Lee DH, Lee CM. et al. Effect of proton pomp inhibitors in bronchiectatic patients with gastroesophageal reflux disease. Korean J Gastroenterol 2016; 68 (01) 10-15
- 58 Rohof WO, Bennink RJ, de Ruigh AA, Hirsch DP, Zwinderman AH, Boeckxstaens GE. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012; 61 (12) 1670-1677
- 59 Olveira G, Olveira C, Doña E. et al. Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study). Clin Nutr 2016; 35 (05) 1015-1022
- 60 Diehl N, Johnson MM. Prevalence of osteopenia and osteoporosis in patients with noncystic fibrosis bronchiectasis. South Med J 2016; 109 (12) 779-783
- 61 Araújo D, Shteinberg M, Aliberti S. et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018; 51 (02) 1-10
- 62 McDonnell MJ, Jary HR, Perry A. et al. Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 2015; 109 (06) 716-726
- 63 Park J, Kim S, Lee YJ. et al. Factors associated with radiologic progression of non-cystic fibrosis bronchiectasis during long-term follow-up. Respirology 2016; 21 (06) 1049-1054
- 64 Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12 (11) 1602-1611
- 65 White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106 (03) 356-360
- 66 Orriols R, Hernando R, Ferrer A, Terradas S, Montoro B. Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration 2015; 90 (04) 299-305
- 67 Loebinger MR, Polverino E, Chalmers JD. et al; iBEST-1 Trial Team. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J 2021; 57 (01) 1-11
- 68 Murray MP, Govan JRW, Doherty CJ. et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183 (04) 491-499
- 69 Polverino E, Goeminne PC, McDonnell MJ. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50 (03) 1-23
- 70 Kovesi T, Creery D, Gilbert NL. et al. Indoor air quality risk factors for severe lower respiratory tract infections in Inuit infants in Baffin Region, Nunavut: a pilot study. Indoor Air 2006; 16 (04) 266-275
- 71 Das L, Kovesi TA. Bronchiectasis in children from Qikiqtani (Baffin) region, Nunavut, Canada. Ann Am Thorac Soc 2015; 12 (01) 96-100
- 72 Singleton R, Morris A, Redding G. et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000; 29 (03) 182-187
- 73 McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012; 142 (01) 159-167
- 74 Hill AT, Haworth CS, Aliberti S. et al; EMBARC/BRR definitions working group. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J 2017; 49 (06) 1-6
- 75 McCullough AR, Tunney MM, Quittner AL, Elborn JS, Bradley JM, Hughes CM. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014; 14: 107
- 76 McCullough AR, Tunney MM, Elborn JS, Bradley JM, Hughes CM. ‘All illness is personal to that individual’: a qualitative study of patients' perspectives on treatment adherence in bronchiectasis. Health Expect 2015; 18 (06) 2477-2488
- 77 McCullough A, Thomas ET, Ryan C. et al. Interventions for enhancing adherence to treatment in adults with bronchiectasis. (Review) Cochrane Database Syst Rev 2015; (11) CD011023
- 78 Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. (Review) Cochrane Database Syst Rev 2015; (11) CD008351
- 79 Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 2017; 9: CD011699
- 80 Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34 (05) 1086-1092
- 81 Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med 2013; 13: 21
- 82 Svenningsen S, Paulin G, Wheatley A. et al. Oscillating positive expiratory pressure therapy in chronic obstructive pulmonary diseases and bronchiectasis. Chest 2013; 741
- 83 Sutton PP, Gemmell HG, Innes N. et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax 1988; 43 (01) 57-60
- 84 Guimarães FS, Moço VJR, Menezes SLS, Dias CM, Salles REB, Lopes AJ. Effects of ELTGOL and Flutter VRP1® on the dynamic and static pulmonary volumes and on the secretion clearance of patients with bronchiectasis. Rev Bras Fisioter 2012; 16 (02) 108-113
- 85 Kurz M, Ahrens P, Zielen S, Hofmann D. Physiotherapy with the VRP-1 device. Objective and subjective results of a comparitive study in children with chronic lung diseases. Pravention und Rehabilation. 2017: 105-109
- 86 Figueiredo PHS, Zin WA, Guimarães FS. Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother Res Int 2012; 17 (01) 12-20
- 87 Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007; 4 (01) 23-30
- 88 Patterson JE, Bradley JM, Hewitt O, Bradbury I, Elborn JS. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques versus Acapella. Respiration 2005; 72 (03) 239-242
- 89 Semwal S, Mitra S, Singh SB. Autogenic drainage versus acapella for airway clearance in patients with bronchiectasis: randomised crossover trial. Cochrane Database Syst Rev 2017; DOI: 10.1002/14651858.CD011699.pub2.
- 90 Thompson CS, Harrison S, Ashley J, Day K, Smith DL. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002; 57 (05) 446-448
- 91 De Oliveira Antunes LC, De Crvalho SM, Borges FD, De Assis VL, De Godoy I. A study of the conventional chest physiotherapy versus Flutter VRP1 in the treatment of patients carrying bronchiectasis. Rev Salusvita 2001; 23-33
- 92 Tsang SM, Jones AY. Postural drainage or flutter device in conjunction with breathing and coughing compared to breathing and coughing alone in improving secretion removal and lung function in patients with acute exacerbation of bronchiectasis: a pilot study. Hong Kong Physiother J 2003; 21 (01) 29-36
- 93 Herrero-Cortina B, Alcaraz V, Vilaró J, Torres A, Polverino E. Impact of Hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J Aerosol Med Pulm Drug Deliv 2018; 31 (05) 281-289
- 94 Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105 (12) 1831-1835
- 95 Nicolson CHH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106 (05) 661-667
- 96 Fuchs HJ, Borowitz DS, Christiansen DH. et al; The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331 (10) 637-642
- 97 Laube BL, Auci RM, Shields DE. et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996; 153 (02) 752-760
- 98 O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113 (05) 1329-1334
- 99 Stass H, Nagelschmitz J, Kappeler D, Sommerer K, Kietzig C, Weimann B. Ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease, and in healthy volunteers. J Aerosol Med Pulm Drug Deliv 2017; 30 (01) 53-63
- 100 De Soyza A, Aksamit T, Bandel TJ. et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 51 (01) 1-12
- 101 Aksamit T, De Soyza A, Bandel TJ. et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 51 (01) 1-1
- 102 Chalmers JD, Cipolla D, Thompson B. et al. Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. Eur Respir J 2020; 56 (04) 1-9
- 103 Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med 2019; 7 (10) 855-869
- 104 Barker AF, O'Donnell AE, Flume P. et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2 (09) 738-749
- 105 Crichton ML, Lonergan M, Barker AF. et al. Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies. Eur Respir J 2020; 56 (01) 1-9
- 106 Blanco-Aparicio M, Saleta Canosa JL, Valiño López P, Martín Egaña MT, Vidal García I, Montero Martínez C. Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis. Chron Respir Dis 2019; 16: 1479973119872513
- 107 Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189 (08) 975-982
- 108 Chang CC, Morris PS, Chang AB. and Cochrane Airways Group. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007; (03) CD006218
- 109 Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; (02) CD006316
- 110 Furumoto A, Ohkusa Y, Chen M. et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26 (33) 4284-4289
- 111 Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60 (11) 943-948
- 112 Lee AL, Hill CJ, Cecins N. et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial. Respir Res 2014; 15 (01) 44
- 113 Mandal P, Sidhu MK, Kope L. et al. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir Med 2012; 106 (12) 1647-1654
- 114 Ong HK, Lee AL, Hill CJ, Holland AE, Denehy L. Effects of pulmonary rehabilitation in bronchiectasis: A retrospective study. Chron Respir Dis 2011; 8 (01) 21-30
- 115 van Zeller M, Mota PC, Amorim A. et al. Pulmonary rehabilitation in patients with bronchiectasis: pulmonary function, arterial blood gases, and the 6-minute walk test. J Cardiopulm Rehabil Prev 2012; 32 (05) 278-283
- 116 Panda A, Bhalla AS, Goyal A. Bronchial artery embolization in hemoptysis: a systematic review. Diagn Interv Radiol 2017; 23 (04) 307-317
- 117 Fruchter O, Schneer S, Rusanov V, Belenky A, Kramer MR. Bronchial artery embolization for massive hemoptysis: long-term follow-up. Asian Cardiovasc Thorac Ann 2015; 23 (01) 55-60
- 118 Lee J-H, Kwon S-Y, Yoon H-I. et al. Haemoptysis due to chronic tuberculosis vs. bronchiectasis: comparison of long-term outcome of arterial embolisation. Int J Tuberc Lung Dis 2007; 11 (07) 781-787
- 119 Annest LS, Kratz JM, Crawford Jr FA. Current results of treatment of bronchiectasis. J Thorac Cardiovasc Surg 1982; 83 (04) 546-550
- 120 Dai J, Zhu X, Bian D, Fei K, Jiang G, Zhang P. Surgery for predominant lesion in nonlocalized bronchiectasis. J Thorac Cardiovasc Surg 2017; 153 (04) 979-985.e1
- 121 Fan LC, Liang S, Lu HW, Fei K, Xu JF. Efficiency and safety of surgical intervention to patients with non-cystic fibrosis bronchiectasis: a meta-analysis. Sci Rep 2015; 5: 17382
- 122 Weber A, Stammberger U, Inci I, Schmid RA, Dutly A, Weder W. Thoracoscopic lobectomy for benign disease--a single centre study on 64 cases. Eur J Cardiothorac Surg 2001; 20 (03) 443-448
- 123 Zhang P, Zhang F, Jiang S. et al. Video-assisted thoracic surgery for bronchiectasis. Ann Thorac Surg 2011; 91 (01) 239-243
- 124 Dupont M, Gacouin A, Lena H. et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125 (05) 1815-1820
- 125 Phua J, Ang YLE, See KC. et al. Noninvasive and invasive ventilation in acute respiratory failure associated with bronchiectasis. Intensive Care Med 2010; 36 (04) 638-647
- 126 Hadda V, Chawla G, Tiwari P. et al. Noninvasive ventilation for acute respiratory failure due to noncystic fibrosis bronchiectasis. Indian J Crit Care Med 2018; 22 (05) 326-331
- 127 Benhamou D, Muir JF, Raspaud C. et al. Long-term efficiency of home nasal mask ventilation in patients with diffuse bronchiectasis and severe chronic respiratory failure: a case-control study. Chest 1997; 112 (05) 1259-1266
- 128 Simonds AK, Elliott MW. Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive and obstructive disorders. Thorax 1995; 50 (06) 604-609
- 129 Weill D, Benden C, Corris PA. et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34 (01) 1-15
- 130 Ramos KJ, Smith PJ, McKone EF. et al; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18 (03) 321-333
- 131 Beirne PA, Banner NR, Khaghani A, Hodson ME, Yacoub MH. Lung transplantation for non-cystic fibrosis bronchiectasis: analysis of a 13-year experience. J Heart Lung Transplant 2005; 24 (10) 1530-1535
- 132 Birch J, Sunny SS, Hester KLM. et al. Outcomes of lung transplantation in adults with bronchiectasis. BMC Pulm Med 2018; 18 (01) 82
- 133 Rusanov V, Fridman V, Wille K, Kramer MR. Lung Transplantation for Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis: A Single-Center Experience. Transplant Proc 2019; 51 (06) 2029-2034
- 134 Chambers DC, Cherikh WS, Harhay MO. et al; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019; 38 (10) 1042-1055
- 135 Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report--2004. J Heart Lung Transplant 2004; 23 (07) 804-815
- 136 Rademacher J, Ringshausen FC, Suhling H. et al. Lung transplantation for non-cystic fibrosis bronchiectasis. Respir Med 2016; 115: 60-65
- 137 Nathan JA, Sharples LD, Exley AR, Sivasothy P, Wallwork J. The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency. J Heart Lung Transplant 2005; 24 (10) 1517-1521